NAGE ChromaDex Cumulative Company Assets

Official company branding of niagenbioscience.com (NAGE)

This chart illustrates that the market value of Chromadex Corp (NAGE) is 99.07, which correlates with the academic approach of Chromadex Corp to dietary supplement development and the retention of scientists through RSUs. The business relies on exclusive molecular ownership rights and regulatory approvals, creating barriers to entry for competitors. Growth is driven by the expansion of contracts in the cellular rejuvenation segment and anticipation of results from new clinical trials.

Company Total Assets: niagenbioscience.com (NAGE) for 03/20/2025 - 10/29/2026

Financial and market metric breakdowns for ChromaDex (NAGE)

- stock value and consensus price forecast:
Market Price Chromadex Corp|NAGE - Price Target Chart
- market capitalization data:
Market Valuation ChromaDex Corporation|NAGE - Enterprise Value
- company book value details:
Net Asset Value per Share ChromaDex|NAGE - Book Capitalization|Capitalization to Book Value Ratio niagenbioscience.com|NAGE - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Chromadex Corp|NAGE - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio ChromaDex Corp.|NAGE - Company Aggregate Debts|Debts to Book Capitalization ChromaDex Corporation|NAGE - Company Long-Term Debt|Company Short-Term Debt ChromaDex|Intermediate Coverage Ratio niagenbioscience.com
- company profitability and valuation multiples indicators:
NAGE - Net Profit
Fundamental valuation:Chromadex Corp
Mass-produced product of ChromaDex Corp

Total assets represent the aggregate of all organizational resources, calculated via the reverse method through return on assets (ROA) to assess the fundamental scale of the business. The asset dynamics of Chromadex Corp (NAGE) demonstrate capital management efficiency, where high resource value combined with exclusive patents for Niagen protects margins and creates an insurmountable barrier for competitors in the NAD+ precursor segment.

Main competitors

Company Assets intuitive.com (ISRG)|Aggregate Company Assets Danaher|Cumulative Company Assets BD (BDX)|Company Total Assets STE|WST - Company Assets|Company Total Assets BAX (Baxter International)|MASI: Total Business Assets|Stevanato Group - Company Total Assets|Company Total Asset Base Teleflex Inc. TFX|MMSI: Company Total Assets|Cumulative Company Assets Nobel Biocare|ICUI (ICU Medical, Inc.) - Company Total Assets|Company Total Assets dentsplysirona.com|Aggregate Company Assets LeMaitre Vascular (LMAT)|Aggregate Company Assets ATRC (AtriCure Inc)|STAAR Surgical Corp - Cumulative Company Assets|Aggregate Asset Value ZIMV|AngioDynamics, Inc. - Company Total Assets|Company Total Asset Base cerus.com CERS|Teknova (TKNO) - Aggregate Company Assets|Total Business Assets MGRM|Aggregate Company Assets Sharps Technology Inc|InfuSystem Inc (INFU) - Company Total Asset Base|Cumulative Company Assets UTMD (Utah Medical Products)|Aggregate Business Assets KRMD|Aggregate Company Assets Nyxoah NYXH|Aggregate Asset Value MBOT|PDEX: Cumulative Company Assets|ZTEK - Company Total Assets|Elutia Inc. (ELUT) - Aggregate Company Assets|Cumulative Company Assets milestonescientific.com|NXGL (NEXGEL) - Company Total Assets|Company Assets Retractable Tech RVP|Aggregate Company Assets Harvard Bioscience (HBIO)|Femasys Corporation - Total Business Assets|Meihua Medical Technologies Co., Ltd. - Cumulative Company Assets|Aggregate Business Assets POAI (Predictive Oncology Inc)|CJMB - Aggregate Company Assets|Company Total Asset Base Atrion Corp. ATRI|NURO: Company Total Assets